Scribe Therapeutics, Inc. (SCTX) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Scribe Therapeutics, Inc. (SCTX) stock forecast summary
Our AI scores Scribe Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Scribe Therapeutics, Inc. is a small-cap company with a market capitalization of $293M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its Current Ratio of 0.57x is the lowest of the 59 peers that report one.
A per-ticker accuracy statistic for SCTX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.3%, sell < +1.7%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SCTX included.
SCTX price chart and AI forecast
How SCTX ranks among 4891 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Scribe Therapeutics, Inc. (SCTX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | SCTX | Rank |
|---|---|---|
| Market Cap | $293M | 60/60 |
Financial Health
| Metric | SCTX | Rank |
|---|---|---|
| Current Ratio | 0.57x | 59/59 |
| Interest Coverage | -10.7x | 17/37 |
| Working Capital | -$34M | 58/58 |
Dividend & Shareholder Information
| Metric | SCTX | Rank |
|---|---|---|
| Shares Outstanding | 19M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $45M | |
| Cash & Short-term Investments | $36M | |
| Total Liabilities | $102M | |
| Short-term Debt | $76M |
SCTX quarterly financials and insider trading
Scribe Therapeutics, Inc. (SCTX) industry peers
Companies classified under the same SEC industry code as Scribe Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| SCTX Scribe Therapeutics, Inc. | $293M | |
| AMGN Amgen Inc | $248.84B | |
| GILD Gilead Sciences, Inc. | $207.84B | |
| MRNA Moderna, Inc. | $96.40B | |
| ARGX Argenx Se | $55.37B | |
| RVMD Revolution Medicines, Inc. | $38.08B | |
| BIIB Biogen Inc. | $36.06B | |
| BNTX Biontech Se | $21.71B | |
| EXEL Exelixis, Inc. | $16.77B | |
| NBIX Neurocrine Biosciences Inc | $16.24B | |
| HALO Halozyme Therapeutics, Inc. | $13.96B | |
| TECH Bio-Techne Corp | $11.41B | |
| QGEN Qiagen N.V. | $11.03B | |
| KYMR Kymera Therapeutics, Inc. | $10.94B | |
| RGEN Repligen Corp | $10.77B | |
| PCVX Vaxcyte, Inc. | $9.21B | |
| KRYS Krystal Biotech, Inc. | $8.90B | |
| IBRX Immunitybio, Inc. | $8.49B | |
| TWST Twist Bioscience Corp | $7.56B | |
| IMVT Immunovant, Inc. | $5.86B | |
| CGON Cg Oncology, Inc. | $5.74B | |
| KOD Kodiak Sciences Inc. | $5.72B | |
| SRRK Scholar Rock Holding Corp | $5.54B | |
| CRSP Crispr Therapeutics Ag | $4.70B | |
| ADPT Adaptive Biotechnologies Corp | $4.28B | |
| RLAY Relay Therapeutics, Inc. | $3.73B | |
| IOVA Iovance Biotherapeutics, Inc. | $3.51B | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.33B | |
| DNLI Denali Therapeutics Inc. | $3.15B | |
| ADMA Adma Biologics, Inc. | $2.96B | |
| BEAM Beam Therapeutics Inc. | $2.67B | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.18B | |
| COAG Hemab Therapeutics Holdings, Inc. | $2.13B | |
| VCEL Vericel Corp | $2.10B | |
| LIFE Atyr Pharma Inc | $2.08B | |
| BCRX Biocryst Pharmaceuticals Inc | $1.95B | |
| REPL Replimune Group, Inc. | $1.90B | |
| VIR Vir Biotechnology, Inc. | $1.86B | |
| MAZE Maze Therapeutics, Inc. | $1.81B | |
| MESO Mesoblast Ltd | $1.81B | |
| ALVO Alvotech | $1.62B | |
| NVAX Novavax Inc | $1.61B | |
| IMCR Immunocore Holdings Plc | $1.46B | |
| TSHA Taysha Gene Therapies, Inc. | $1.33B | |
| VOR Vor Biopharma Inc. | $1.15B | |
| CGEM Cullinan Therapeutics, Inc. | $1.01B | |
| ODTX Odyssey Therapeutics, Inc. | $907M | |
| GLUE Monte Rosa Therapeutics, Inc. | $874M | |
| IMTX Immatics N.V. | $829M | |
| MGTX Meiragtx Holdings Plc | $817M | |
| PRME Prime Medicine, Inc. | $807M | |
| SANA Sana Biotechnology, Inc. | $700M | |
| SLBT Sl Science Holding Ltd | $679M | |
| DNA Ginkgo Bioworks Holdings, Inc. | $671M | |
| SLDB Solid Biosciences Inc. | $663M | |
| AURA Aura Biosciences, Inc. | $657M | |
| FDMT 4d Molecular Therapeutics, Inc. | $621M | |
| DBVT Dbv Technologies S.A. | $616M | |
| CADL Candel Therapeutics, Inc. | $615M | |
| VALN Valneva Se | $551M |
Where SCTX sits on the market map
Scribe Therapeutics, Inc. (SCTX) stock news
Loading...
Scribe Therapeutics, Inc. (SCTX) stock forecast FAQ
What is the Scribe Therapeutics, Inc. (SCTX) stock forecast?
Our AI scores Scribe Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Scribe Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for SCTX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Scribe Therapeutics, Inc. forecasts updated?
Scribe Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Scribe Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, SCTX included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.